A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
A Phase II, Multicentre, Open-label Study to Evaluate the Pharmacokinetic, Safety and Preliminary Efficacy of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Subjects With Severe Hemophilia A
Sponsor: Jiangsu Gensciences lnc.
A PHASE2 clinical study on Severe Hemophilia A, this trial is completed. The trial is conducted by Jiangsu Gensciences lnc. and has accumulated 5 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jun 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Jul 2022 — Jun 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2022 — Jul 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Jiangsu Gensciences lnc.
For direct contact, visit the study record on ClinicalTrials.gov .